TARS · Tarsus Pharmaceuticals, Inc.
$65.33
+4.04 (+6.59%)
At close · Aug 6
Market Cap
$2.64B
Shares
43.88M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$65.33
Open$57.63
Day$57.63–66.24
52W$40.55–85.25
Avg vol 30d1.3M
Short int5.8M · 13.2% float · 3.2d
Short vol57%
Last earningsAug 6, 2026
DataOct 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
+7%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
55%
mid-range
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+3%
trailing
YTD return
−20%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $61 › 200d $68 — 200d above 50d
Institutional flow
Accumulating
67 of 253 funds reported for Jun 30 · net +444.8K sh shares · +7 new
Insider flow
Distributing
Net -$877.4K over 90 days · 100% sells
Short interest
Falling
13.18% of float · ▼ -1.8% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
253 holders — near 3-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+147%
Y/Y
EPS growth
+48%
Y/Y
Free cash flow
$-22.3M
Balance sheet
$111.2M
net cash
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
XDEMVY net product sales
· full-year 2026
Initiated
$685M – $705M
prior FY $451.36M
midpoint +54.0% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
+7%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
55%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $61 › 200d $68 — 200d above 50d
Institutional flow
Accumulating
67 of 253 funds reported for Jun 30 · net +444.8K sh shares · +7 new
Insider flow
Distributing
Net -$877.4K over 90 days · 100% sells
Short interest
Falling
13.18% of float · ▼ -1.8% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
253 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $41
Now $65 · 55%
52-wk high $85
vs 200-day avg -5%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margins | 93% | Q2 2026 | — |
|
|
|||
| Unaided awareness of Demodex blepharitis | 30% | the second quarter 2026 | — |
| XDEMVY net product sales | $173.91M | FY2026 Q2 | +69.4% |
|
|
|||
| bottles of XDEMVY delivered to patients | 400,000 | full-year 2025 | — |
| commercial, Medicare, and Medicaid covered lives | 90% | fourth quarter 2025 | — |
| gross-to-net discount | 45% | full-year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TARS
this stock
Tarsus Pharmaceuticals, Inc.
|
$2.64B | -20.2% | +146.7% | — | 13.2% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +8.6% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.8% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | +0.3% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +4.1% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TARS | +9.7% | +1.9% | +3.3% | +10.7% | -20.2% |
| SPY | +3.6% | +2.2% | +12.8% | +2.9% | +12.7% |
| vs SPY | +6.1% | -0.4% | -9.5% | +7.8% | -32.9% |
Key facts
CIK
1819790
CUSIP
87650L103
13F (30d)
57 filings
57 filers
Visit website
Investor relations